Maxalt Smelt

Rizatriptan, the active ingredient in Maxalt Smelt, is a Triptan (5‑HT1B/1D receptor agonist) presented as an oral tablet for oral use. It is indicated for the acute treatment of migraine attacks, with or without aura, in adult patients.\n\nGNH India supplies Maxalt Smelt as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Rizatriptan belongs to the Triptan class and is used to treat migraine attacks.\n\nMigraine (with or without aura): Provides rapid relief by aborting the headache phase of a migraine episode.\nMigraine prophylaxis: Not indicated; the drug is intended for acute, not preventive, therapy.\nOther headache disorders: Not approved; use is limited to migraine.

Rizatriptan may cause a range of adverse reactions, most of which are mild and transient.\n\nCommon Side Effects:\n- Nausea\n- Dizziness\n- Fatigue\n- Dry mouth\n- Tingling or numbness in the fingers or toes\n- Chest discomfort or pressure\n\nSerious or Rare Side Effects:\n- Coronary artery spasm leading to chest pain or myocardial infarction\n- Serotonin syndrome, especially when combined with other serotonergic agents\n- Severe hypertension\n- Allergic reactions such as rash, angioedema, or anaphylaxis\n- Stroke or transient ischemic attack

Before prescribing Maxalt Smelt, clinicians should evaluate cardiovascular risk and concomitant medication use.\n\nCardiovascular disease: Avoid in patients with uncontrolled hypertension, coronary artery disease, or history of myocardial infarction.\nHemiplegic or basilar migraine: Contraindicated due to increased risk of cerebrovascular events.\nConcomitant serotonergic drugs: Use caution to prevent serotonin syndrome.\nPregnancy and lactation: Safety not established; prescribe only if benefit outweighs potential risk.\nDrug interactions: Review all current medications for potential interactions.\nStore at ambient temperature below 25°C: keep in the original pack, protect from moisture.

Rizatriptan can interact with several drug classes, requiring careful management.\n\nMajor Interactions (Avoid):\n- Monoamine oxidase inhibitors (MAOIs) taken within 14 days\n- Other triptans or ergot derivatives (risk of additive vasoconstriction)\n- Selective serotonin reuptake inhibitors (SSRIs) or serotonin‑norepinephrine reuptake inhibitors (SNRIs) (risk of serotonin syndrome)\n\nModerate Interactions (Monitor Closely):\n- Antihypertensive agents (possible additive blood pressure effects)\n- Strong CYP3A4 inhibitors (may increase rizatriptan plasma levels)\n- Oral contraceptives (potential for altered efficacy)\n- Antihistamines or sedatives (may enhance dizziness or fatigue)